ClinicalTrials.gg
RecruitingNCT06206369VASCULAIDRETROUpdated Oct 5, 2026

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression

An observational study in Aneurysm Abdominal and Peripheral Arterial Disease, sponsored by Amsterdam UMC, location VUmc. Recruiting at 6 sites in 6 countries. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Amsterdam UMC, location VUmc · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.
Updated Oct 5, 2026Eligibility revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
11,000
Ages
40 Years to 90 Years
Sex
All
01

Study summary

The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). The study plans to gather and analyze data from at least 5000 AAA and 6000 PAD patients, combining existing cohorts and retrospectively collected data. During this project, AI tools will be developed to perform automatic anatomical segmentation and analyses on multimodal imaging. AI prediction algorithms will be developed based on multisource data (imaging, medical history, -omics).

Read the detailed description

To date, it is unknown which abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD) patients will suffer cardiovascular events or in which patients the AAA or PAD will progress. In the VASCULAID project, the VASCULAID-RETRO study aims to leverage data from existing cohorts and retrospectively collected data to develop artificial intelligence (AI) algorithms able to evaluate the risk of cardiovascular events and extent of disease progression.

In order to build and train the algorithms for the predictions, we plan to retrospectively enroll at least 5000 AAA and 6000 PAD patients AI-tools will be applied to the patient data. Automatic anatomical segmentation on images and image analysis on US, CTA and MRI will be performed. Also, algorithms to predict cardiovascular events and AAA or PAD progression based on multi-source data analysis will be developed.

Patient data from European clinical consortium partners is available. This consortium has access to big cohorts with relevant data for the envisioned study that will be used to enrich the existing registries. These data will be used to refine the algorithms developed for the prediction of cardiovascular events and AAA/PAD progression.

02

Conditions studied

  • Aneurysm Abdominal
  • Peripheral Arterial Disease

Keywords

  • Artificial Intelligence, Prediction models, Image analysis, Abdominal Aortic Aneurysms, Peripheral Arterial Disease
03

In context

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

This study's planned enrollment of 11,000 is above the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.

Browse Aortic Aneurysm, Abdominal studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males and females between 40 and 90 years of age with an abdominal aortic aneurysm and/or peripheral arterial disease.

Eligibility criteria

Inclusion Criteria AAA:

  • Males and females
  • 40-90 years old,
  • Infrarenal, juxtarenal, suprarenal, iliac aneurysms (defined as 1.5x its normal diameter), and mycotic aneurysms.
  • Starting AAA diameter >3cm,
  • Patients that both have had or did not have interventions or ruptures.

Exclusion Criteria AAA:

  • Patients with solely an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.

Inclusion Criteria PAD:

  • Males and females,
  • 40-90 years old,
  • All PAD patients; all Fontaine stages 1,2,3, and 4.

Exclusion Criteria PAD: None

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
11,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Abdominal Aortic Aneurysm patients

    Other: No intervention, retrospective study

  • Peripheral Arterial Disease patients

    Other: No intervention, retrospective study

Interventions

  • OtherNo intervention, retrospective study

    No intervention, retrospective study

06

What researchers measure

Primary outcomes

  1. Development of disease progression prediction algorithms

    The primary goal of this retrospective study is to develop and train algorithms to predict disease progression and risk of cardiovascular events in AAA and PAD patients by leveraging multi-parametric data from 5000 AAA (\>1000 in AUMC) and 6000 PAD (\>1000 in AUMC) patients from existing cohorts and biobanks.

    Time frame: 3 years

Secondary outcomes

  1. Internal validation of disease progression prediction algorithms

    The secondary objective will be the internal validation of the developed algorithms using data from retrospective cohorts.

    Time frame: 3 years

07

Study locations

6 of 6 sites recruiting
  • Hospital District of Helsinki and Uusimaa (HUS)
    Helsinki, Finland
    Recruiting
    • Riikka Tulamo · Contact
  • Asklepios kliniken hamburg
    Hamburg, Germany
    Recruiting
    • Christian Behrendt · Contact
  • Amsterdam UMC
    Amsterdam, Netherlands
    Recruiting
    • Kak Khee Yeung · Contact
  • University Hospital Center of São João
    Porto, Portugal
    Recruiting
    • Marina Dias-Neto · Contact
  • University Clinical Centre of Serbia
    Belgrade, Serbia
    Recruiting
    • Igor Koncar · Contact
  • Oxford University Hospitals
    Oxford, United Kingdom
    Recruiting
    • Regent Lee · Contact
08

References and documents

Publications

  • Rijken L, Zwetsloot S, Smorenburg S, Wolterink J, Isgum I, Marquering H, van Duivenvoorde J, Ploem C, Jessen R, Catarinella F, Lee R, Bera K, Buisan J, Zhang P, Dias-Neto M, Raffort J, Lareyre F, Muller C, Koncar I, Tomic I, Zivkovic M, Djuric T, Stankovic A, Venermo M, Tulamo R, Behrendt CA, Smit N, Schijven M, van den Born BJ, Delewi R, Jongkind V, Ayyalasomayajula V, Yeung KK. Developing Trustworthy Artificial Intelligence Models to Predict Vascular Disease Progression: the VASCUL-AID-RETRO Study Protocol. J Endovasc Ther. 2025 Feb 7:15266028251313963. doi: 10.1177/15266028251313963. Online ahead of print. PubMed 39921236 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for May 2029, 66 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 16, 2024
StartActual
Oct 31, 2023
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 criteria edited, 10 added
What changed in the criteria
  • AddedInclusion Criteria AAA:
  • AddedMales and females
  • Added40-90 years old,
  • EditedMales and females, 40-90 years old, with an AAA >3cm. This includes patients with infrarenalInfrarenal, juxtarenal, suprarenal, iliac aneurysms (defined as 1.5x its normal diameter) aneurysms, as well asand mycotic aneurysms. Patients that have had interventions or ruptures will also be included
  • AddedStarting AAA diameter >3cm,
  • AddedPatients that both have had or did not have interventions or ruptures.
  • AddedExclusion Criteria AAA:
  • EditedPatients with solely an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.
  • AddedInclusion Criteria PAD:
  • AddedMales and females,
  • Added40-90 years old,
  • EditedMales and females, 40-90 years old, allAll PAD patients (; all Fontaine stages 1,2,3, and 4).
  • AddedExclusion Criteria PAD: None
Oct 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39921236 ↗
Oct 5, 2026
Sponsor
Collaborators added: University of Belgrade; collaborators removed: Faculty of Medicine, University of Belgrade
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39921236 ↗
    Eligibility 3 criteria edited, 10 added
    What changed in the criteria
    • AddedInclusion Criteria AAA:
    • AddedMales and females
    • Added40-90 years old,
    • EditedMales and females, 40-90 years old, with an AAA >3cm. This includes patients with infrarenalInfrarenal, juxtarenal, suprarenal, iliac aneurysms (defined as 1.5x its normal diameter) aneurysms, as well asand mycotic aneurysms. Patients that have had interventions or ruptures will also be included
    • AddedStarting AAA diameter >3cm,
    • AddedPatients that both have had or did not have interventions or ruptures.
    • AddedExclusion Criteria AAA:
    • EditedPatients with solely an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.
    • AddedInclusion Criteria PAD:
    • AddedMales and females,
    • Added40-90 years old,
    • EditedMales and females, 40-90 years old, allAll PAD patients (; all Fontaine stages 1,2,3, and 4).
    • AddedExclusion Criteria PAD: None
    Sponsor Collaborators added: University of Belgrade; collaborators removed: Faculty of Medicine, University of Belgrade
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06206369
Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Technical University of Twente, Universidade do Porto, Centre Hospitalier Universitaire de Nice, Stichting Allai, University of Belgrade, Brightfish Be, Hospital District of Helsinki and Uusimaa, University of Bergen, Asklepios Kliniken Hamburg GmbH, University of Oxford, VINČA INSTITUTE OF NUCLEAR SCIENCES Belgrado
Responsible party
Kak Khee Yeung (Professor Dr., Amsterdam UMC, location VUmc) — Principal investigator
First posted
Jan 16, 2024
Start date
Oct 31, 2023
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Kak Khee Yeung, MD, PhD
Contact
k.yeung@amsterdamumc.nl
+31 6 14278725
Lotte Rijken, Msc.
Contact
l.rijken@amsterdamumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion